Our
Pipeline
EVOLVE-104 is a first-in-class biotherapeutic with potential to address a wide range of solid tumors with high selectivity. EVOLVE-105 represents a best- in-class molecule to improve patient outcomes in relapsed or treatment refractory B cell lymphoma. Our best-in-class EVOLVE-106 program addresses important unmet needs in selected solid tumor targets. EVOLVE-101 is a first-in-class molecule targeting a novel tumor antigen for the treatment of B cell malignancies and particular myeloid malignancies. We anticipate entering the clinic with our first program in 2024.
Discovery
Lead Optimization
IND-ENABLING
Candidate Selection
EVOLVE-104
Solid Tumors
First – in – Class Target
EVOLVE-105
B Cell Malignancies
Best – in – Class Target
EVOLVE-106
Solid Tumors
Best – in – Class Target
EVOLVE-101
B Cell Malignancies and AML
First – in – Class Target
T Cell Exhaustion
Engineering CAR-T Durability
CRISPR – Cas9 Discovery Platform